177 related articles for article (PubMed ID: 25261661)
41. HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC.
Wu F; Zhang J; Liu Y; Zheng Y; Hu N
Cell Physiol Biochem; 2013; 32(6):1566-76. PubMed ID: 24335195
[TBL] [Abstract][Full Text] [Related]
42. Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients.
Dacosta-Noble P; Costantini A; Dumenil C; Dumoulin J; Helly de Tauriers P; Giraud V; Labrune S; Emile JF; Alvarez JC; Chinet T; Giroux Leprieur E
PLoS One; 2019; 14(7):e0219080. PubMed ID: 31260495
[TBL] [Abstract][Full Text] [Related]
43. [Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer].
Hu Y; Lin DM; Cheng SJ; Liu YN; Feng FY
Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(37):2611-4. PubMed ID: 17198586
[TBL] [Abstract][Full Text] [Related]
44. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
45. Prognostic and clinicopathological value of osteopontin expression in non-small cell lung cancer: a meta-analysis and systematic review.
Song Y; Li H; Jiang Q; Wu L
Biomarkers; 2024 Mar; 29(2):105-113. PubMed ID: 38376506
[TBL] [Abstract][Full Text] [Related]
46. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Yoh K; Ishii G; Yokose T; Minegishi Y; Tsuta K; Goto K; Nishiwaki Y; Kodama T; Suga M; Ochiai A
Clin Cancer Res; 2004 Mar; 10(5):1691-7. PubMed ID: 15014021
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance of serum osteopontin levels in small cell lung cancer.
Xu C; Yuan Q; Wang W; Chi C; Zhang Q; Li L; Yang R; Wang Y
BMC Pulm Med; 2020 Sep; 20(1):235. PubMed ID: 32873264
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.
Jin Y; Tong DY; Chen JN; Feng ZY; Yang JY; Shao CK; Li JP
PLoS One; 2012; 7(10):e48575. PubMed ID: 23119061
[TBL] [Abstract][Full Text] [Related]
49. Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density.
Yu TT; Han ZG; Shan L; Tao J; Zhang T; Yuan SF; Shen HL
Asian Pac J Cancer Prev; 2014; 15(1):29-32. PubMed ID: 24528042
[TBL] [Abstract][Full Text] [Related]
50. Association between nuclear expression of retinoic acid receptor alpha and beta and clinicopathological features and prognosis of advanced non-small cell lung cancer.
Muñiz-Hernández S; Huerta-Yepez S; Hernández-Pedro N; Ramírez-Tirado LA; Aviles-Salas A; Maldonado A; Hernández-Cueto D; Baay-Guzmán G; Arrieta O
Int J Clin Oncol; 2016 Dec; 21(6):1051-1061. PubMed ID: 27306217
[TBL] [Abstract][Full Text] [Related]
51. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
Chen HH; Yan JJ; Chen WC; Kuo MT; Lai YH; Lai WW; Liu HS; Su WC
Lung Cancer; 2012 Feb; 75(2):228-34. PubMed ID: 21788094
[TBL] [Abstract][Full Text] [Related]
52. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.
Wilop S; Crysandt M; Bendel M; Mahnken AH; Osieka R; Jost E
Onkologie; 2008 Dec; 31(12):665-70. PubMed ID: 19060504
[TBL] [Abstract][Full Text] [Related]
53. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
54. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
[TBL] [Abstract][Full Text] [Related]
55. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
Carbone F; Grossi F; Bonaventura A; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Biello F; Rossi G; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
Clin Exp Metastasis; 2019 Oct; 36(5):449-456. PubMed ID: 31376097
[TBL] [Abstract][Full Text] [Related]
56. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.
Blasberg JD; Pass HI; Goparaju CM; Flores RM; Lee S; Donington JS
J Clin Oncol; 2010 Feb; 28(6):936-41. PubMed ID: 20085934
[TBL] [Abstract][Full Text] [Related]
57. Weight loss at the time of diagnosis is not associated with prognosis in patients with advanced-stage non-small cell lung cancer.
Sahin C; Omar M; Tunca H; Kalemci S; Ozseker B; Akbaba G; Tanriverdi O
J BUON; 2015; 20(6):1576-84. PubMed ID: 26854455
[TBL] [Abstract][Full Text] [Related]
58. Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer.
Ouyang X; Huang Y; Jin X; Zhao W; Hu T; Wu F; Huang J
Onco Targets Ther; 2018; 11():5933-5941. PubMed ID: 30275702
[TBL] [Abstract][Full Text] [Related]
59. High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients.
Koren A; Rijavec M; Sodja E; Kern I; Sadikov A; Kovac V; Korosec P; Cufer T
Oncotarget; 2017 Apr; 8(15):25384-25394. PubMed ID: 28445986
[TBL] [Abstract][Full Text] [Related]
60. [Keap1 expression for predicting the chemoresistance and prognosis of advanced non-small cell lung cancer].
Cao B; Zhu X; Chen S; Xiao Y; Liang L
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):591-6. PubMed ID: 23075683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
